Tafluprost ophthalmic solution

(Zioptan®)

Zioptan®

Latest News

loading GIF

Drug updated on 4/15/2024

Dosage FormSolution (topical; 0.015 mg/mL)
Drug ClassProstaglandin analogs
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Tafluprost ophthalmic solution (Zioptan) is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
  • Two studies provided a comparative analysis of Zioptan's safety and effectiveness against other drugs used for the same condition.
  • One study demonstrated that latanoprostene bunod was numerically superior to tafluprost in lowering intraocular pressure, though the difference was not statistically significant. This indicates that while there may be some advantages to using latanoprostene bunod over tafluprost, these are not conclusively better based on this analysis.
  • The second study assessed the impact of combining topical nonsteroidal anti-inflammatory drugs with prostaglandin analogues like tafluprost. It showed enhanced intraocular pressure reduction when combination therapy is used; however, specific details related to tafluprost were not provided.
  • Neither study provided detailed information about safety evaluations or subgroup considerations specifically related to Zioptan compared with other drugs beyond measures of effectiveness.
  • Further research would be necessary due to the lack of available data regarding factors such as age, severity of condition, or presence of comorbidities.